Definium Therapeutics (NASDAQ:DFTX) Receives Buy Rating from Canaccord Genuity Group

Definium Therapeutics (NASDAQ:DFTX)‘s stock had its “buy” rating restated by analysts at Canaccord Genuity Group in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $38.00 price target on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 60.00% from the company’s current price.

A number of other research analysts have also issued reports on DFTX. Leerink Partners boosted their target price on Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a report on Tuesday, April 21st. HC Wainwright boosted their target price on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Piper Sandler reissued an “overweight” rating and issued a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Finally, Oppenheimer reissued an “outperform” rating and issued a $40.00 target price on shares of Definium Therapeutics in a report on Thursday, April 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Definium Therapeutics has an average rating of “Buy” and an average price target of $37.92.

Definium Therapeutics Stock Performance

Shares of NASDAQ:DFTX traded down $0.02 during trading on Tuesday, reaching $23.75. The company had a trading volume of 352,613 shares, compared to its average volume of 1,871,060. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -9.54 and a beta of 2.37. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The stock’s fifty day moving average price is $22.38 and its 200 day moving average price is $18.06. Definium Therapeutics has a fifty-two week low of $6.34 and a fifty-two week high of $26.25.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, equities research analysts predict that Definium Therapeutics will post -2.3 EPS for the current year.

Institutional Trading of Definium Therapeutics

A number of institutional investors have recently bought and sold shares of DFTX. Russell Investments Group Ltd. boosted its position in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares in the last quarter. BIT Capital GmbH purchased a new stake in Definium Therapeutics during the third quarter worth $26,000. Fifth Third Bancorp boosted its position in Definium Therapeutics by 5,593.2% during the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after purchasing an additional 3,300 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares in the last quarter. Finally, FNY Investment Advisers LLC purchased a new stake in Definium Therapeutics during the third quarter worth $107,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.